重组人α-2C干扰素治疗原发性血小板增多症的疗效
Therapeutic effect of human recombinant interferon-alpha-2C in essential thrombocythaemia.
作者信息
Velu T, Delwiche F, Gangji D, Monsieur R, Flament J, Stryckmans P, Wybran J, Bellens R
出版信息
Oncology. 1985;42 Suppl 1:10-4. doi: 10.1159/000226078.
PMID:4080296
Abstract
Human recombinant interferon-alpha 2C was given to 4 patients with essential thrombocythaemia. Three patients achieved a complete remission on day 19 +/- 1 and the 4th achieved a partial remission. After 4 weeks of induction therapy, a maintenance therapy of twice weekly intramuscular injections of 5 X 10(6) or 10 X 10(6) IU was instituted but did not maintain the remission.
摘要
将重组人干扰素α-2C给予4例原发性血小板增多症患者。3例患者在第19±1天实现完全缓解，第4例实现部分缓解。诱导治疗4周后，开始每周两次肌肉注射5×10⁶或10×10⁶国际单位的维持治疗，但未能维持缓解状态。
Zotero 插件